Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) – Equities researchers at HC Wainwright increased their Q4 2024 earnings per share (EPS) estimates for shares of Entrada Therapeutics in a note issued to investors on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.66) per share for the quarter, up from their previous estimate of ($0.67). HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is $0.98 per share.
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The company had revenue of $94.69 million for the quarter, compared to analyst estimates of $55.00 million.
View Our Latest Stock Analysis on Entrada Therapeutics
Entrada Therapeutics Stock Up 3.1 %
Shares of TRDA opened at $19.82 on Friday. The company has a market cap of $741.66 million, a P/E ratio of 12.47 and a beta of -0.26. Entrada Therapeutics has a fifty-two week low of $10.75 and a fifty-two week high of $19.95. The firm’s 50 day moving average price is $16.40 and its 200 day moving average price is $15.70.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC boosted its holdings in Entrada Therapeutics by 427.6% in the first quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after purchasing an additional 11,965 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Entrada Therapeutics by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,078,908 shares of the company’s stock worth $15,288,000 after buying an additional 13,742 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Entrada Therapeutics in the 1st quarter valued at $79,000. Bank of New York Mellon Corp grew its position in shares of Entrada Therapeutics by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 125,436 shares of the company’s stock valued at $1,787,000 after buying an additional 14,838 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Entrada Therapeutics by 25.3% during the 2nd quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock worth $526,000 after acquiring an additional 7,452 shares in the last quarter. Hedge funds and other institutional investors own 86.39% of the company’s stock.
Insider Buying and Selling at Entrada Therapeutics
In other news, COO Nathan J. Dowden sold 1,904 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $15.07, for a total transaction of $28,693.28. Following the completion of the transaction, the chief operating officer now directly owns 125,996 shares of the company’s stock, valued at approximately $1,898,759.72. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, COO Nathan J. Dowden sold 1,904 shares of Entrada Therapeutics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.07, for a total transaction of $28,693.28. Following the completion of the sale, the chief operating officer now directly owns 125,996 shares of the company’s stock, valued at approximately $1,898,759.72. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Natarajan Sethuraman sold 2,642 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $15.09, for a total transaction of $39,867.78. Following the transaction, the insider now owns 183,816 shares of the company’s stock, valued at approximately $2,773,783.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,187 shares of company stock valued at $155,947 in the last quarter. Corporate insiders own 7.59% of the company’s stock.
Entrada Therapeutics Company Profile
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Read More
- Five stocks we like better than Entrada Therapeutics
- How to Evaluate a Stock Before Buying
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 11/4 – 11/8
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.